T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety ...

At the beginning of 2025, Helen Swan was told she had months to live. A Scottish grandmother-to-be has started ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding surgery and harsh treatments.